Literature DB >> 22489

Complement-fixing antibody response in pneumococcal pneumonia.

J D Coonrod, B Rylko-Bauer.   

Abstract

Previous studies of complement-fixing antibodies to pneumococcal capsular polysaccharides in humans have yielded conflicting results. We studied 65 sera from 25 patients with pneumococcal pneumonia, using both fresh sera and heat-inactivated sera with added human complement. Only 4 of the 25 patients developed detectable levels of complement-fixing anticapsular antibody. Of the 25 patients, 22 developed detectable levels of hemagglutinating anticapsular antibody, indicating that they were able to develop an immunological response during the infection. Most of the antibody detected by hemagglutination was sensitive to 2-mercaptoethanol, but some 2-mercaptoethanol-resistant antibody was also detected. In studies with rabbit antiserum, the complement fixation test was found to be as sensitive as the hemagglutination test for detection of anticapsular antibody. It is not clear why detectable levels of complement-fixing antibody do not develop more often in patients with pneumococcal pneumonia. Studies of purified anticapsular antibody would be of interest to determine whether or not these antibodies are restricted to immunoglobulin subclasses having a limited capacity to fix complement.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 22489      PMCID: PMC421280          DOI: 10.1128/iai.18.3.617-623.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Requirement of avian C'1 for fixation of guinea pig complement by avian antibody-antigen complexes.

Authors:  H N BENSON; H P BRUMFIELD; B S POMEROY
Journal:  J Immunol       Date:  1961-11       Impact factor: 5.422

2.  The effect of unheated normal bovine serum on the complement-fixing activity of heat inactivated bovine antiserum with homologous antigen. I. Dialysis studies.

Authors:  C E RICE; J CARRIERE
Journal:  J Immunol       Date:  1961-12       Impact factor: 5.422

3.  A quantitative complement fixation test: titration of luetic sera by the unit of 50 per cent hemolysis.

Authors:  G J STEIN; D VAN NGU
Journal:  J Immunol       Date:  1950-07       Impact factor: 5.422

4.  Biologic activities of aggregated gamma-globulin. 8. Aggregated immunoglobulins of different classes.

Authors:  T Ishizaka; K Ishizaka; S Salmon; H Fudenberg
Journal:  J Immunol       Date:  1967-07       Impact factor: 5.422

5.  Rheumatoid factor and the fixation of complement.

Authors:  N J Zvaifler
Journal:  Ann N Y Acad Sci       Date:  1969-12-10       Impact factor: 5.691

6.  Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin.

Authors:  M H Kaplan; J E Volanakis
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

7.  Pneumococcal pneumonia: capsular polysaccharide antigenemia and antibody responses.

Authors:  J D Coonrod; D P Drennan
Journal:  Ann Intern Med       Date:  1976-03       Impact factor: 25.391

8.  Radioimmunoassay of human C-reactive protein and levels in normal sera.

Authors:  D R Claus; A P Osmand; H Gewurz
Journal:  J Lab Clin Med       Date:  1976-01

9.  Immune response to acute otitis media in children. I. Serotypes isolated and serum and middle ear fluid antibody in pneumococcal otitis media.

Authors:  J L Sloyer; V M Howie; J H Ploussard; A J Ammann; R Austrian; R B Johnston
Journal:  Infect Immun       Date:  1974-06       Impact factor: 3.441

10.  Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers.

Authors:  W J Yount; M M Dorner; H G Kunkel; E A Kabat
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  1 in total

1.  Role of complement component C1q in phagocytosis of Listeria monocytogenes by murine macrophage-like cell lines.

Authors:  C Alvarez-Dominguez; E Carrasco-Marin; F Leyva-Cobian
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.